CRANBURY, N.J., Feb. 13, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD - News), a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases, today announced financial results for the fourth quarter and full-year ended December 31, 2011. The Company also highlighted recent and upcoming milestones related to its pharmacological chaperone development pipeline and reiterated full-year 2012 financial guidance.
